Shree Ganesh Rem

Why is Shree Ganesh Remedies Ltd falling/rising?

As of 18-Jul, Shree Ganesh Remedies Ltd's stock price is 648.20, down 0.39% with a 6.17% decline over the past week. Despite this short-term drop, the stock has a year-to-date increase of 39.94%, indicating strong long-term performance and increased investor interest.

As of 18-Jul, Shree Ganesh Remedies Ltd's stock price is currently at 648.20, reflecting a decrease of 2.55 (-0.39%). The stock has experienced a decline of 6.17% over the past week, contrasting with a positive return of 0.75% from the Sensex during the same period. However, it has shown a strong performance over the longer term, with a year-to-date increase of 39.94%, significantly outperforming the Sensex, which has fallen by 8.30% in the same timeframe.<BR><BR>Today's performance indicates a slight positive trend, as the stock has outperformed its sector by 1.7% and has shown signs of a trend reversal after two consecutive days of decline. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 46.87% compared to the 5-day average, suggesting growing interest in the stock despite the current price drop.<BR><BR>The stock's moving averages indicate that it is performing better than the 50-day, 100-day, and 200-day averages, although it is below the 5-day and 20-day averages. This mixed performance in moving averages may contribute to the current volatility in the stock price.<BR><BR>Overall, while the stock is currently experiencing a decline, its strong long-term performance and increased investor participation suggest that it may be a hold for investors looking for potential recovery in the near future.

Which are the latest news on Shree Ganesh Rem?

What does Shree Ganesh Rem do?

Shree Ganesh Remedies Ltd manufactures pharmaceutical intermediates and fine chemicals, classified as a Micro Cap company with a market cap of INR 801 Cr. As of March 2026, it reported net sales of 33 Cr and a net profit of 6 Cr.

Overview:<BR>Shree Ganesh Remedies Ltd is engaged in the manufacturing of pharmaceutical intermediates and fine chemicals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as a Private Limited Company on April 27, 1995, in Ahmedabad, Gujarat, and was later converted into a Public Limited Company on July 28, 2017. The latest quarterly results report net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 33 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 6 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 801 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 41.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.03<BR>- Return on Equity: 10.90%<BR>- Price to Book: 4.90<BR><BR>Contact Details:<BR>- Address: Plot No 6011, GIDC Ankleshwar Gujarat : 393002<BR>- Tel: 91-2646-227777<BR>- Email: investors@ganeshremedies.com<BR>- Website: http://www.ganeshremedies.com

How big is Shree Ganesh Rem?

As of 10th June, Shree Ganesh Remedies Ltd has a market capitalization of 801.00 Cr, with recent net sales of 109.30 Cr and a net profit of 17.77 Cr.

As of 10th June, Shree Ganesh Remedies Ltd has a market capitalization of 801.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 109.30 Cr and a Net Profit of 17.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 145.16 Cr and Total Assets of 191.94 Cr.

Who are in the management team of Shree Ganesh Rem?

The management team of Shree Ganesh Rem includes Chandubhai Kothia (Chairman & Managing Director), Gunjan Kothia, Parth Kothia (Whole-time Directors), Priyam Shah, Jayesh Savjani, Vaishaliben Vadodariya, Maulikkumar Sudani (Independent Directors), and Parul Sahani (Director), overseeing the company's strategic direction and governance.

The management team of Shree Ganesh Rem includes the following individuals:<BR><BR>1. **Chandubhai Kothia** - Chairman & Managing Director<BR>2. **Gunjan Chandulal Kothia** - Whole-time Director<BR>3. **Parth Chandulal Kothia** - Whole-time Director<BR>4. **Priyam Surendra Shah** - Independent Director<BR>5. **Jayesh Savjani** - Independent Director<BR>6. **Vaishaliben Kanjibhai Vadodariya** - Independent Director<BR>7. **Parul Sahani** - Director<BR>8. **Maulikkumar Sudani** - Independent Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

Who are the peers of the Shree Ganesh Rem?

Shree Ganesh Rem's peers include Bharat Parenter., Kopran, Anlon Healthcare, Sigachi Indust., Anuh Pharma, Kilitch Drugs, Zim Laboratories, Amanta Healthcar, and Remus Pharma. In terms of management risk, growth, and capital structure, Shree Ganesh Rem is on par with several peers, while its 1-year return is -8.24%, better than Sigachi Indust. but worse than Zim Laboratories.

Peers: The peers of Shree Ganesh Rem are Bharat Parenter., Kopran, Anlon Healthcare, Sigachi Indust., Anuh Pharma, Kilitch Drugs, Zim Laboratories, Amanta Healthcar, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anlon Healthcare, Sigachi Indust., Anuh Pharma, and Remus Pharma, while Average management risk is found at Bharat Parenter., Kopran, Shree Ganesh Rem, Zim Laboratories, and Amanta Healthcar. Below Average management risk is noted at Kilitch Drugs. Growth is Excellent at Anlon Healthcare and Kilitch Drugs, while Average growth is seen at Bharat Parenter., Kopran, Shree Ganesh Rem, Zim Laboratories, and Amanta Healthcar. Below Average growth is reported for Sigachi Indust. and Anuh Pharma. Excellent capital structure is present at Anlon Healthcare, Sigachi Indust., Anuh Pharma, Shree Ganesh Rem, and Remus Pharma, while Good capital structure is found at Kopran and Kilitch Drugs, and Below Average capital structure is noted at Amanta Healthcar.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Zim Laboratories at 4.71%, while the peer with the lowest is Sigachi Indust. at -62.71%. Shree Ganesh Rem's 1-year return is -8.24%, which is higher than Sigachi Indust. but lower than Zim Laboratories. Additionally, peers with negative six-month returns include Sigachi Indust. and Amanta Healthcar.

Should I buy, sell or hold Shree Ganesh Remedies Ltd?

Are Shree Ganesh Remedies Ltd latest results good or bad?

Shree Ganesh Remedies Ltd's latest results show strong sequential revenue growth of 57.27% and a 102.91% increase in net profit quarter-on-quarter. However, year-on-year comparisons reveal a 4.86% decline in net profit and reduced profit margins, indicating underlying profitability challenges despite the revenue recovery.

Shree Ganesh Remedies Ltd's latest results present a mixed picture. On one hand, the company achieved a significant sequential improvement in revenue, reporting ₹33.20 crores for Q4 FY26, which is a 57.27% increase from the previous quarter and a 35.90% increase year-on-year. Additionally, net profit surged by 102.91% quarter-on-quarter to ₹6.27 crores, indicating a strong recovery from the previous quarter.<BR><BR>However, the year-on-year comparison reveals some concerning trends. Despite the revenue growth, net profit decreased by 4.86% compared to the same quarter last year. Furthermore, the operating margin fell sharply to 34.28% from 40.40% in Q4 FY25, and the profit after tax margin also declined to 18.89% from 26.98%. This indicates that while the company is generating more sales, it is struggling with rising costs and profitability pressures.<BR><BR>In summary, while Shree Ganesh Remedies has shown strong revenue growth and a recovery in net profit from the last quarter, the decline in profit margins and year-on-year profit suggests underlying challenges that could impact future performance. Therefore, the results can be seen as good in terms of revenue recovery but concerning regarding profitability.

When is the next results date for Shree Ganesh Remedies Ltd?

The next results date for Shree Ganesh Remedies Ltd is 14 May 2026.

The next results date for Shree Ganesh Remedies Ltd is scheduled for 14 May 2026.

How has been the historical performance of Shree Ganesh Rem?

Shree Ganesh Rem's historical performance shows fluctuating trends, with net sales and profits declining from March 2024 to March 2025, despite growth in total assets. Recent results indicate a decrease in profitability and cash flow, contrasting with earlier growth.

Answer:<BR>The historical performance of Shree Ganesh Rem shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Shree Ganesh Rem's net sales decreased from INR 125.90 crore in March 2024 to INR 108.60 crore in March 2025, following a significant rise from INR 49.08 crore in March 2021. The total operating income mirrored this trend, remaining at INR 108.60 crore in March 2025, down from INR 125.90 crore in the previous year. The company's operating profit (PBDIT) also saw a decline to INR 42.95 crore in March 2025 from INR 44.88 crore in March 2024, although it had increased from INR 15.74 crore in March 2021. Profit before tax decreased to INR 31.27 crore in March 2025 from INR 38.16 crore in March 2024, while profit after tax followed suit, dropping to INR 23.07 crore from INR 28.11 crore. The company's total assets grew to INR 191.94 crore in March 2025 from INR 170.94 crore in March 2024, and total liabilities increased to INR 191.94 crore from INR 170.94 crore in the same period. Cash flow from operating activities remained stable at INR 30.00 crore in both March 2025 and March 2024, but the net cash outflow was recorded at INR 5.00 crore in March 2025, contrasting with a net inflow of INR 7.00 crore in March 2024. Overall, while Shree Ganesh Rem has shown growth in certain areas over the years, recent performance indicates a decline in profitability and cash flow.

Is Shree Ganesh Rem overvalued or undervalued?

As of October 10, 2025, Shree Ganesh Rem is fairly valued with a PE ratio of 29.32 and an EV to EBITDA of 17.00, but has underperformed with a year-to-date stock return of -21.58% compared to the Sensex's 5.58%.

As of 10 October 2025, the valuation grade for Shree Ganesh Rem has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 29.32, an EV to EBITDA of 17.00, and a ROCE of 19.10%. In comparison to its peers, Sun Pharma has a higher PE ratio of 34.96 and an EV to EBITDA of 23.7, while Dr. Reddy's Labs shows a more attractive valuation with a PE of 18.58 and an EV to EBITDA of 12.26.<BR><BR>Despite the recent valuation adjustment, Shree Ganesh Rem has underperformed in the short term, with a year-to-date stock return of -21.58% compared to a Sensex return of 5.58%. This performance suggests that while the stock may be fairly valued, it faces challenges in the current market environment.

Is Shree Ganesh Rem technically bullish or bearish?

As of September 25, 2025, the market trend has shifted to a moderately strong bearish stance, indicated by bearish daily moving averages and Bollinger Bands, despite mixed signals from the MACD and KST across different time frames.

As of 25 September 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the daily moving averages indicating bearishness, and both the weekly and monthly Bollinger Bands also signaling bearish trends. The MACD shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, suggesting mixed signals across time frames. The KST aligns with this by being mildly bullish weekly and mildly bearish monthly. Overall, the bearish trend is reinforced by the recent price decline and underperformance compared to the Sensex over multiple periods.

Who are the top shareholders of the Shree Ganesh Rem?

The top shareholder of Shree Ganesh Rem is Chandulal Manubhai Kothia, holding 48.76%, followed by public shareholder Gunjan Jayantibhai Dhorajiya at 1.7%. Individual investors own 24.89%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Shree Ganesh Rem include the promoters, with Chandulal Manubhai Kothia being the largest shareholder, holding 48.76% of the company. The highest public shareholder is Gunjan Jayantibhai Dhorajiya, who holds 1.7%. Additionally, individual investors collectively hold 24.89% of the shares. There is also one foreign institutional investor (FII) that holds a very small percentage, at 0.01%. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

What is the bonus history of the Shree Ganesh Rem?

Shree Ganesh Remedies' recent bonus history includes a 1:5 bonus announced on November 1, 2021, with a record date of November 2, 2021, and a previous 3:26 bonus issued on October 6, 2020, with a record date of October 7, 2020.

Shree Ganesh Remedies has a notable bonus history. The most recent bonus issue was a 1:5 ratio, which was announced with an ex-date of November 1, 2021, and the record date was November 2, 2021. Prior to that, the company had a bonus issue with a ratio of 3:26, which had an ex-date of October 6, 2020, and a record date of October 7, 2020. If you have any more questions about the company or its financials, feel free to ask!

Has Shree Ganesh Rem declared dividend?

Shree Ganesh Remedies Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 7, 2023. Despite this, the recent total returns show declines over shorter periods, while longer-term performance remains strong.

Shree Ganesh Remedies Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 07 Sep 2023<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.84%, with a dividend return of 0%, resulting in a total return of -14.84%.<BR><BR>Over the past year, the price return was -24.98%, with a dividend return of 0%, leading to a total return of -24.98%.<BR><BR>In the 2-year period, the price return was 62.3%, with a dividend return of 0.14%, resulting in a total return of 62.44%.<BR><BR>For the 3-year period, the price return was 142.1%, with a dividend return of 0.45%, leading to a total return of 142.55%.<BR><BR>In the 4-year period, the price return was 127.4%, with a dividend return of 0.85%, resulting in a total return of 128.25%.<BR><BR>Over the last 5 years, the price return was 940.28%, with a dividend return of 6.40%, leading to a total return of 946.68%.<BR><BR>Overall, while Shree Ganesh Remedies Ltd has declared a dividend, the recent total returns show significant declines over shorter periods, contrasting with strong performance over the longer term. The dividend yield remains at 0%, indicating that the recent dividends have not contributed to returns in the short term.